The WFC3 Galactic Bulge Treasury Program: A First Look at Resolved Stellar Population Tools

[Abridged] When WFC3 is installed on HST, the community will have powerful new tools for investigating resolved stellar populations. The WFC3 Galactic Bulge Treasury program will obtain deep imaging on 4 low-extinction fields. These non-proprietary data will enable a variety of science investigations not possible with previous data sets. To aid in planning for the use of these data and for future proposals, we provide an introduction to the program, its photometric system, and the associated calibration effort. The observing strategy is based upon a new 5-band photometric system spanning the UV, optical, and near-infrared. With these broad bands, one can construct reddening-free indices of Teff and [Fe/H]. Besides the 4 bulge fields, the program will target 6 fields in well-studied star clusters, spanning a wide range of [Fe/H]. The cluster data serve to calibrate the indices, provide population templates, and correct the transformation of isochrones into the WFC3 photometric system. The bulge data will shed light on the bulge formation history, and will also serve as population templates for other studies. One of the fields includes 12 candidate hosts of extrasolar planets. CMDs are the most popular tool for analyzing resolved stellar populations. However, due to degeneracies among Teff, [Fe/H], and reddening in traditional CMDs, it can be difficult to draw robust conclusions from the data. The 5-band system used for the bulge Treasury observations will provide indices that are roughly orthogonal in Teff and [Fe/H], and we argue that model fitting in an index-index diagram will make better use of the information than fitting separate CMDs. We provide simulations to show the expected data quality and the potential for differentiating between different star-formation histories.Comment: Accepted for publication in The Astronomical Journal. 9 pages, 8 figures, latex, AJ forma

Transiting extrasolar planetary candidates in the Galactic bulge

More than 200 extrasolar planets have been discovered around relatively nearby stars, primarily through the Doppler line shifts owing to the reflex motions of their host stars, and more recently through transits of some planets across the face of the host stars. The detection of planets with the shortest known periods, 1.2 to 2.5 days, has mainly resulted from transit surveys which have generally targeted stars more massive than 0.75 M_sun. Here we report the results from a planetary transit search performed in a rich stellar field towards the Galactic bulge. We discovered 16 candidates with orbital periods between 0.4 and 4.2 days, five of which orbit stars of 0.44 to 0.75 M_sun. In two cases, radial-velocity measurements support the planetary nature of the companions. Five candidates have orbital periods below 1.0 day, constituting a new class of ultra-short-period planets (USPPs), which occur only around stars of less than 0.88 M_sun. This indicates that those orbiting very close to more luminous stars might be evaporatively destroyed, or that jovian planets around lower-mass stars might migrate to smaller radii.Comment: To appear in October 5, 2006 issue of Natur

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

PURPOSE: Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene. Migalastat, a pharmacological chaperone, binds to specific mutant forms of α-galactosidase A to restore lysosomal activity. METHODS: A pharmacogenetic assay was used to identify the α-galactosidase A mutant forms amenable to migalastat. Six hundred Fabry disease-causing mutations were expressed in HEK-293 (HEK) cells; increases in α-galactosidase A activity were measured by a good laboratory practice (GLP)-validated assay (GLP HEK/Migalastat Amenability Assay). The predictive value of the assay was assessed based on pharmacodynamic responses to migalastat in phase II and III clinical studies. RESULTS: Comparison of the GLP HEK assay results in in vivo white blood cell α-galactosidase A responses to migalastat in male patients showed high sensitivity, specificity, and positive and negative predictive values (≥0.875). GLP HEK assay results were also predictive of decreases in kidney globotriaosylceramide in males and plasma globotriaosylsphingosine in males and females. The clinical study subset of amenable mutations (n = 51) was representative of all 268 amenable mutations identified by the GLP HEK assay. CONCLUSION: The GLP HEK assay is a clinically validated method of identifying male and female Fabry patients for treatment with migalastat

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data.

Aim: Late-onset Pompe disease is characterized by progressive loss of muscular and respiratory function. Until recently, standard of care was enzyme replacement therapy (ERT) with alglucosidase alfa. Second-generation ERTs avalglucosidase alfa (aval) and cipaglucosidase alfa with miglustat (cipa+mig) are now available. Without head-to-head trials comparing aval with cipa+mig, an indirect treatment comparison is informative and timely for understanding potential clinical differentiation. Materials & methods: A systematic literature review was performed to identify relevant studies on cipa+mig and aval. Using patient-level and aggregate published data from randomized controlled trials (RCTs) and phase I/II and open-label extension (OLE) trials, a multi-level network meta-regression was conducted, adjusting for various baseline covariates, including previous ERT duration, to obtain relative effect estimates on 6-minute walk distance (6MWD, meters [m]) and forced vital capacity (FVC, % predicted [pp]). Analyses of two networks were conducted: Network A, including only RCTs, and network B, additionally including single-arm OLE and phase I/II studies. Results: Network B (full evidence analysis) showed that cipa+mig was associated with a relative increase in 6MWD (mean difference 28.93 m, 95% credible interval [8.26-50.11 m]; Bayesian probability 99.7%) and FVC (2.88 pp [1.07-4.71 pp]; >99.9%) compared with aval. The comparison between cipa+mig and aval became more favorable for cipa+mig with increasing previous ERT duration for both end points. Analysis of network A showed that cipa+mig was associated with a relative decrease in 6MWD (-10.02 m [-23.62 to 4.00 m]; 91.8%) and FVC (-1.45 pp [-3.01 to 0.07 pp]; 96.8%) compared with aval. Conclusion: Cipa+mig showed a favorable effect versus aval when all available evidence was used in the analysis

104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease:a phase III open-label extension study (ATB200-07)

The phase III double-blind PROPEL study compared the novel two-component therapy cipaglucosidase alfa + miglustat (cipa + mig) with alglucosidase alfa + placebo (alg + pbo) in adults with late-onset Pompe disease (LOPD). This ongoing open-label extension (OLE; NCT04138277) evaluates long-term safety and efficacy of cipa + mig. Outcomes include 6-min walk distance (6MWD), forced vital capacity (FVC), creatine kinase (CK) and hexose tetrasaccharide (Hex4) levels, patient-reported outcomes and safety. Data are reported as change from PROPEL baseline to OLE week 52 (104 weeks post-PROPEL baseline). Of 118 patients treated in the OLE, 81 continued cipa + mig treatment from PROPEL (cipa + mig group; 61 enzyme replacement therapy [ERT] experienced prior to PROPEL; 20 ERT naïve) and 37 switched from alg + pbo to cipa + mig (switch group; 29 ERT experienced; 8 ERT naive). Mean (standard deviation [SD]) change in % predicted 6MWD from baseline to week 104 was + 3.1 (8.1) for cipa + mig and − 0.5 (7.8) for the ERT-experienced switch group, and + 8.6 (8.6) for cipa + mig and + 8.9 (11.7) for the ERT-naïve switch group. Mean (SD) change in % predicted FVC was − 0.6 (7.5) for cipa + mig and − 3.8 (6.2) for the ERT-experienced switch group, and − 4.8 (6.5) and − 3.1 (6.7), respectively, in ERT-naïve patients. CK and Hex4 levels improved in both treatment groups by week 104 with cipa + mig treatment. Three patients discontinued the OLE due to infusion-associated reactions. No new safety signals were identified. Cipa + mig treatment up to 104 weeks was associated with overall maintained improvements (6MWD, biomarkers) or stabilization (FVC) from baseline with continued durability, and was well tolerated, supporting long-term benefits for patients with LOPD. Trial registration number: NCT04138277; trial start date: December 18, 2019.</p

Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies

Abstract Background Fabry disease (FD) is a genetic disorder resulting from deficiency of the lysosomal enzyme α-galactosidase A (α-Gal A), which leads to globotriaosylceramide (GL-3) accumulation in multiple tissues. We report on the safety and pharmacodynamics of migalastat hydrochloride, an investigational pharmacological chaperone given orally at 150 mg every-other-day. Methods Two open-label uncontrolled phase 2 studies of 12 and 24 weeks (NCT00283959 and NCT00283933) in 9 males with FD were combined. At multiple time points, α-Gal A activity and GL-3 levels were quantified in blood cells, kidney and skin. GL-3 levels were also evaluated through skin and renal histology. Results Compared to baseline, increased α-Gal A activity of at least 50% was demonstrated in blood, skin and kidney in 6 of 9 patients. Patients’ increased α-Gal A activities paralleled the α-Gal A increases observed in vitro in HEK-293 cells transfected with the corresponding mutant form of the enzyme. The same 6 patients who demonstrated increases of α-Gal A activity also had GL-3 reduction in skin, urine and/or kidney, and had α-Gal A mutations that responded in transfected cells incubated with the drug. The 3 patients who did not show a consistent response in vivo had α-Gal A mutations that did not respond to migalastat HCl in transfected cells. Migalastat HCl was well tolerated. Conclusions Migalastat HCl is a candidate pharmacological chaperone that provides a novel genotype-specific treatment for FD. It enhanced α-Gal A activity and resulted in GL-3 substrate decrease in patients with responsive GLA mutations. Phase 3 studies are ongoing. Trial registration Clinicaltrial.gov: NCT00283959 and NCT0028393

Animal-sediment relationships: Evaluating the 'Pearson–Rosenberg paradigm' in Mediterranean coastal lagoons

SUMMARY: We investigated the applicability of the Pearson–Rosenberg (P–R) conceptual model describing a generalized pattern of response of benthic communities in relation to organic enrichment to Mediterranean Sea coastal lagoons. Consistent with P–R model predictions, benthic diversity and abundance showed two different peaks at low (>2.5–5 mg g1) and high (>25–30 mg g1) total organic carbon (TOC) ranges, respectively. We identified TOC thresholds indicating that risks of reduced benthic diversity should be relatively low at TOC values about 28 mg g1, and intermediate at values in-between. Predictive ability within these ranges was high based on results of re-sampling simulation. While not a direct measure of causality, it is anticipated that these TOC thresholds should serve as a general screening-level indicator for evaluating the likelihood of reduced sediment quality and associated bioeffects in such eutrophic systems of the Mediterranean Sea

Early understory succession following catastrophic wind damage in a deciduous forest

Early succession was followed in a 2.5-ha gap created by a severe wind storm in a 5.5-ha fragment of eastern North American deciduous forest. Understory vegetation cover by species, light, soil moisture, and levels of several major nutrients were measured in 1 × 2 m census plots 3 years prior to the disturbance. Coincidentally, the storm felled 50-55% of the trees over a portion of these plots. Vegetation cover by species was again measured in all plots 3 years following the disturbance. Species were grouped by growth form, and group cover values used to examine changes in the composition of the vegetation and to determine whether these changes were correlated with any measured predisturbance environmental variables. Given the size of the gap, shade-intolerant tree species were expected to increase but did not, most likely because of repression by the shrub layer. The main response to the disturbance appeared to occur through reorganization of existing vegetation. The value of predisturbance species cover data and limitations of our sample sizes are discussed. </jats:p